Traditionally, MET, a biguanide-derived drug, is used in the treatment of diabetes mellitus type 2 as a modulator of insulin sensitivity by decreasing hepatic gluconeogenesis and lipogenesis. This evidence concerns the gene INS and diabetes mellitus.